Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children | Zendy

Ruth A. Karron | Zendy; Jocelyn San Mateo | Zendy; B. Thumar | Zendy; Nicolaas Schaap | Zendy; Ursula J. Buchholz | Zendy; Alexander C. Schmidt | Zendy; E. J. Bartlett | Zendy; Brian R. Murphy | Zendy; Peter L. Collins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children

Author(s) -

Ruth A. Karron,

Jocelyn San Mateo,

B. Thumar,

Nicolaas Schaap,

Ursula J. Buchholz,

Alexander C. Schmidt,

E. J. Bartlett,

Brian R. Murphy,

Peter L. Collins

Publication year - 2014

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piu104

Subject(s) - human parainfluenza virus , medicine , virology , vaccination , immunology , population , attenuated vaccine , pediatrics , virus , biology , virulence , environmental health , biochemistry , gene

We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research